Diffusion Tensor Breast MRI (DTI)
Status
Conditions
Treatments
Details and patient eligibility
About
The breast MRI is used in the preoperative scenario to evaluate the extension of a newly diagnosed breast cancer and to screen the contralateral breast. The scan consists of a series of images taken after the use of intravascular contrast media that may detect areas of enhancement that look malignant, but are actually benign tissue, producing a false positive result. The investigators aim to evaluate a novel MRI sequence of images that does not use contrast, diffusion tensor imaging (DTI). Addition of DTI sequence does not add significantly to the time of standard breast MRI exam. This novel technique provides improved detection of tissue microstructure and is able to differentiate malignant from benign tumor. Hence, the investigators hypothesize that DTI may decrease the false positive rate when compared with standard dynamic contrast-enhanced (DCE) MRI.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Female of any race, ethnicity and lifetime risk.
- Eighteen years or older.
- Known recent diagnosis of a breast cancer and normal clinical breast exam of the contralateral side.
- Self-detected lump suspicious for breast cancer that it has not been biopsied yet.
Exclusion criteria
- Inability to understand the consent form
- Pregnant or nursing
- Currently taking tamoxifen, evista (raloxifene), or an aromatase inhibitor for adjuvant therapy or chemoprevention
- Physically unable to lie down on her belly for at least 10 minutes.
- Have had benign needle biopsy of the breast performed within 3 months, or breast surgery within 1 year prior to MRI exam.
Trial design
Primary purpose
Allocation
Interventional model
Masking
267 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal